Kenya Authorized to Produce HIV Prevention Pill
Merck licensed seven generic manufacturers to expand global access to the drug alimatravir.
Updated on Sept. 28, 2026 in Biotech
Live Poll
Should countries prioritize local manufacturing of essential medical supplies to improve access and supply chain stability?
Kenya has received a license to begin domestic production of the HIV-prevention medication alimatravir. Merck has granted royalty-free rights to seven generic drugmakers to supply the treatment to 129 low- and middle-income nations.
Why it matters
This initiative aims to bolster medical supply chain autonomy across Africa and lower costs for national health systems. The project seeks to provide rapid, affordable access to critical HIV prevention tools in developing countries.
The drug alimatravir provides protective benefits just one hour after ingestion. The medication is projected to cost national health systems $5 per person annually.
The players
Merck
This global pharmaceutical corporation holds the intellectual property for the HIV prevention medication alimatravir.
Bill and Melinda Gates Foundation
This private foundation has invested $100 million in the drug's trials and pledged an additional $80 million for further testing and delivery.
The Universal Corporation
This firm has been designated to lead the manufacturing of the HIV-prevention pill within Kenya.
Unitaid
This international organization provides funding and technical support to help build medical manufacturing capacity in Africa.
The details
The Universal Corporation will lead the manufacturing efforts in Kenya, which is one of three African nations selected for production. Unitaid is providing technical support and funding to three regional facilities to facilitate the rollout.
Timeline
Clinical studies began in Uganda, Kenya, and South Africa last year.
Merck announced the new licensing agreements this past Friday.
Clinical trial results are expected to be released next year.
The Tech Race
This development follows the Medicines Patent Pool's voluntary licensing model for expanding access to affordable medicine in developing markets. It reflects a broader shift toward regional autonomy in pharmaceutical manufacturing to reduce dependence on foreign supply chains.
The initiative aims to provide national health systems with HIV prevention tools at a cost of $5 per person annually. Increased regional production could eventually lead to more stable supply chains and reduced wait times for patients in participating countries.
The takeaway
By moving production closer to the populations most in need, this project seeks to transform how low-income nations handle HIV prevention. The effort highlights the importance of philanthropic investment in accelerating late-stage medical trials.
What happens next
Clinical trial results for the drug are anticipated to be published next year, which will provide definitive efficacy data to guide the global rollout.
Further reading
Learn more about the latest developments in Biotech.
Source note: This article includes information reported by Nation.
Live Poll
Should countries prioritize local manufacturing of essential medical supplies to improve access and supply chain stability?
